Welcome to our dedicated page for Oncolytics Biotech news (Ticker: ONCY), a resource for investors and traders seeking the latest updates and insights on Oncolytics Biotech stock.
Oncolytics Biotech Inc (ONCY) is a clinical-stage biotech company advancing pelareorep, an innovative oncolytic virus immunotherapy targeting multiple cancer types. This dedicated news hub provides investors and researchers with centralized access to corporate developments and scientific progress updates.
Track critical updates including clinical trial results, regulatory milestones, and strategic partnerships. Our curated collection features press releases spanning Phase 2 breast cancer studies, pancreatic cancer research advancements, and manufacturing capacity expansions. Regular updates ensure timely awareness of key developments in HR+/HER2- metastatic breast cancer trials and other high-priority programs.
Discover verified information on pelareorep's mechanism of action, trial design specifics, and intellectual property developments. The resource eliminates the need by aggregating essential updates from randomized controlled studies to manufacturing quality initiatives. Bookmark this page for efficient monitoring of Oncolytics' progress in transforming cancer treatment through viral immunotherapy approaches.
Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapy company focused on oncology, has announced its participation in Canaccord Genuity's 44th Annual Growth Conference. The event will take place from August 13-15, 2024 at the InterContinental Boston Hotel.
Chief Medical Officer Dr. Thomas Heineman will engage in a fireside chat on Tuesday, August 13, 2024, at 8:30 a.m. ET in the Hutchinson Room. The presentation will be accessible via webcast on the company's Investor Relations page.
Additionally, Oncolytics' management team will be available for one-on-one investor meetings during the conference. Interested parties can schedule meetings through the conference website, Canaccord representatives, or by emailing jpatton@oncolytics.ca.
Oncolytics Biotech reported Q2 2024 financial results and operational highlights for its pelareorep immunotherapy program. Key updates include:
- Productive FDA feedback on planned registration trial for HR+/HER2- metastatic breast cancer
- On track to report overall survival results from BRACELET-1 breast cancer study in H2 2024
- Dosed first patient in new GOBLET pancreatic cancer cohort supported by PanCAN funding
- Collaboration with GCAR for adaptive registration-enabling pancreatic cancer trial
Financial highlights:
- Cash position of $24.9 million, providing runway into 2025
- Q2 2024 net loss of $7.3 million vs $7.4 million in Q2 2023
- R&D expenses increased to $4.6 million in Q2 2024 vs $3.7 million in Q2 2023
Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapy company focused on oncology, has announced a conference call and webcast scheduled for Thursday, August 1, 2024, at 4:30 p.m. ET. The event will provide a corporate update and discuss financial results for the second quarter of 2024. Investors and interested parties can join via North American toll-free number (800) 836-8184 or international number (646) 357-8785, using conference ID 34386. A webcast will also be available on the company's Investor Relations page and archived for three months. A dial-in replay will be accessible for one week after the call.
Oncolytics Biotech announced productive feedback from the U.S. FDA on its Type C meeting, supporting the planned potential registration-enabling trial for pelareorep in HR+/HER2- metastatic breast cancer (mBC). The FDA endorsed progression-free survival as the primary endpoint and overall survival as a key secondary endpoint. The study will include patients who have failed hormonal therapy and have received no more than one line of ADC therapy. This step builds on promising data from previous studies (BRACELET-1, IND-213, and AWARE-1) showcasing pelareorep's efficacy and immunotherapeutic action. Oncolytics is on track to report overall survival data from the BRACELET-1 trial in H2 2024, advancing their mission to offer better treatment options for breast cancer patients.
Oncolytics Biotech announced that Dr. Matt Coffey, President and CEO, will take a medical leave of absence effective immediately. Wayne Pisano, Chair of the Board, will assume the role of interim CEO during Dr. Coffey's absence. Despite this leadership change, Oncolytics remains optimistic about its ongoing clinical trials and strategic priorities.
The company highlighted its key developments, such as the expected overall survival data from the BRACELET-1 breast cancer study in H2 2024 and the advancement of their pelareorep combination therapy towards a registration-enabling study for pancreatic cancer.
Wayne Pisano, who has extensive experience in the pharmaceutical and biotech industries, will lead the company during this transitional period. He has previously held significant positions, including President of VaxInnate and CEO of Sanofi Pasteur.
Oncolytics Biotech has dosed the first patient in the GOBLET study cohort, which assesses the combination of pelareorep and modified FOLFIRINOX (mFOLFIRINOX) with or without atezolizumab in newly diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC) patients. The study, funded by a US$5 million grant from PanCAN’s Therapeutic Accelerator Award, aims to evaluate the objective response rate (ORR) and safety of this combination therapy. This collaboration involves AIO-Studien-gGmbH and is part of a larger Phase 1/2 multiple indication study for gastrointestinal cancers. The outcomes could potentially lead to the development of new pancreatic cancer treatment regimens.
Oncolytics Biotech presented two abstracts at the 2024 ASCO Annual Meeting that highlight the potential of pelareorep in treating metastatic pancreatic ductal adenocarcinoma (PDAC) and its immunotherapeutic mechanism of action.
The first abstract discusses a new cohort in the GOBLET study, which will test pelareorep combined with mFOLFIRINOX, with and without atezolizumab. This cohort is funded by a $5 million grant, expecting enrollment to start this quarter.
The second abstract highlights pelareorep's ability to induce tumor-infiltrating lymphocytes (TILs) expansion, correlating with improved tumor response across multiple cancers, providing further support for its use as a backbone immunotherapy.
On May 16, 2024, Oncolytics Biotech announced the voting results from its Annual General Meeting held on May 15, 2024. Representing 41.34% of outstanding shares, shareholders elected eight directors with the following votes: Patricia Andrews (84.78%), Deborah M. Brown (74.81%), Matthew C. Coffey (70.97%), Angela Holtham (77.53%), James T. Parsons (74.81%), Wayne Pisano (72.88%), Jonathan Rigby (76.81%), and Bernd R. Seizinger (81.49%).
Additionally, shareholders approved the number of directors at eight and reappointed the auditors for the coming year. For more details, refer to the management information circular at SEDAR.
Oncolytics Biotech (NASDAQ: ONCY) announced a preliminary collaboration with the Global Coalition for Adaptive Research (GCAR) to include pelareorep in a planned pancreatic cancer trial. The trial will use a combination therapy of checkpoint inhibition and chemotherapy, and aims to accelerate the development timeline while reducing costs. The adaptive Phase 2/3 design will assess multiple investigational therapies for metastatic pancreatic cancer, providing a potential registration pathway. Updated data from the GOBLET study showed a 62% objective response rate with pelareorep, nearly triple the historical control trials. This strategic collaboration is expected to advance the development of pelareorep to address urgent patient needs.
Oncolytics Biotech® reported first-quarter 2024 financial results and operational highlights including advancing pelareorep to registration-enabling studies, obtaining FDA Type C meeting for HR+/HER2- metastatic breast cancer, and anticipated milestones like overall survival data in H2 2024. The company has a cash position of $29.6 million providing runway into 2025.
FAQ
What is the current stock price of Oncolytics Biotech (ONCY)?
What is the market cap of Oncolytics Biotech (ONCY)?
